Cannabis in Brazil

Cannabis in Brazil

Contrary to expectations, the national government did not advance hemp legislation for medical and industrial purposes in 2023. Instead, it opted to sidestep a potentially contentious debate, prioritising a comprehensive tax reformulation on its agenda. Despite this federal stance, several states in Brazil, with São Paulo taking a prominent lead due to its significant population and economic influence, independently approved the use of cannabinoid medicine within the public health system.

Euromonitor International's Cannabis in Brazil market report offers a comprehensive guide to the size and shape of this emerging market opportunity at a national level. It provides the latest retail sales data (historic date range), allowing you to identify the key cannabinoid categories driving growth. It outlines the regulatory, cultural and commercial context and offers strategic analysis of key factors influencing the market – legislative developments both current and future, economic/lifestyle influences, illicit consumption, product innovation, distribution and pricing trends. Forecasts to 2028 illustrate how the market is set to expand and change.

Product coverage: Adult-Use Cannabis, CBD & Other Non-Intoxicating Cannabinoids, Medical Cannabis.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report??
* Get a detailed picture of the Cannabis market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.